嗜酸性食管炎
医学
杜皮鲁玛
免疫学
哮喘
炎症
特应性皮炎
过敏性炎症
免疫球蛋白E
发病机制
奥马佐单抗
鼻息肉
白细胞介素13
免疫系统
疾病
细胞因子
白细胞介素
抗体
病理
作者
Michele Ghezzi,Elena Pozzi,Luisa Abbattista,Luisa Lonoce,Gianvincenzo Zuccotti,Enza D’Auria
出处
期刊:Children (Basel)
[Multidisciplinary Digital Publishing Institute]
日期:2021-12-09
卷期号:8 (12): 1165-1165
被引量:39
标识
DOI:10.3390/children8121165
摘要
Allergic diseases represent a global burden. Although the patho-physiological mechanisms are still poorly understood, epithelial barrier dysfunction and Th2 inflammatory response play a pivotal role. Barrier dysfunction, characterized by a loss of differentiation, reduced junctional integrity, and altered innate defence, underpins the pathogenesis of allergic diseases. Epithelial barrier impairment may be a potential therapeutic target for new treatment strategies Up now, monoclonal antibodies and new molecules targeting specific pathways of the immune response have been developed, and others are under investigation, both for adult and paediatric populations, which are affected by atopic dermatitis (AD), asthma, allergic rhinitis (AR), chronic rhinosinusitis with nasal polyps (CRSwNP), or eosinophilic esophagitis (EoE). In children affected by severe asthma biologics targeting IgE, IL-5 and against IL-4 and IL-13 receptors are already available, and they have also been applied in CRSwNP. In severe AD Dupilumab, a biologic which inhibits both IL-4 and IL-13, the most important cytokines involved in inflammation response, has been approved for treatment of patients over 12 years. While a biological approach has already shown great efficacy on the treatment of severe atopic conditions, early intervention to restore epithelial barrier integrity, and function may prevent the inflammatory response and the development of the atopic march.
科研通智能强力驱动
Strongly Powered by AbleSci AI